Archives
-
DNase I (RNase-free): Mechanism and Evidence
2026-10-05
DNase I (RNase-free) is a calcium-dependent endonuclease for DNA removal in RNA-focused workflows. The product description supports applications in RNA extraction, RT-PCR, in vitro transcription sample preparation, and chromatin research, but independent validation remains matrix- and lot-specific.
-
Coelenterazine for ROS and Luciferase Signals
2026-10-05
Coelenterazine is a luminescent enzyme substrate used in luciferase reporters, BRET, and chemiluminescent detection of selected reactive oxygen species. Its signal can support oxidative stress measurement and cancer-associated reactive oxygen species imaging, but enzyme output, direct ROS chemistry, solvent effects, and biological perturbation must be interpreted separately.
-
Anti-CD4 Antibody: A CAR-M Evidence Guide
2026-10-04
This evidence-focused guide explains how Anti-CD4 Antibody (Ibalizumab) fits into immune-cell interpretation without confusing CD4 phenotyping with CAR-M therapy. It also examines the mechanistic innovation, translational promise, and limitations of a 2026 hepatocellular carcinoma study.
-
JWH 133 and Liver Iron Overload: What the Data Show
2026-10-03
JWH 133 is examined here as a mechanistic probe of CB2 receptor signaling in liver iron overload. The analysis connects the reported hepatocyte and Kupffer-cell findings with translational limits, evidence strength, and future research questions.
-
Psoralen-Induced Cholestasis via ERK1/2
2026-10-02
The 2024 study identifies ERK1/2 activation as a mechanistic link between the estrogen-like natural products psoralen and isopsoralen and cholestatic liver injury in zebrafish larvae. By combining estrogenic biomarkers, bile-flow phenotyping, bile-acid gene analysis, and pharmacological rescue, the work establishes a testable framework for studying phytoestrogen-associated cholestasis while highlighting important translational limitations.
-
Prednisone: From Mechanism to Translational Strategy
2026-10-01
Prednisone is more than a corticosteroid reagent: it is a mechanistically defined perturbation tool for linking lymphocyte cell-cycle control, cytokine signaling, apoptosis, exposure conditions, and translational risk. This article outlines how to design stronger assays and interpret findings across cellular, animal, and complex-matrix models.
-
Tetrazolium (chloride) for Tissue Viability
2026-10-01
Tetrazolium (chloride), also called Tetrazolium Red or TTC, converts dehydrogenase activity into a spatially resolved red formazan signal. This guide translates that chemistry into practical cell viability, mitochondrial function, and ischemic tissue workflows, with troubleshooting strategies for reproducible lesion quantification.
-
I-BET151 (GSK1210151A) Lab Workflow Guide
2026-09-30
This practical guide explains how to use I-BET151 (GSK1210151A), SKU B1500, to study BRD2, BRD3, and BRD4-dependent transcriptional effects in biochemical and cell-based cancer biology workflows. It supports controlled assay development but should not be used for diagnostic, therapeutic, or medical applications, and biochemical potency values should not be treated as cellular dosing instructions.
-
Actinomycin D Workflows for Transcriptional Stress
2026-09-30
Actinomycin D converts transcriptional inhibition into a measurable experimental variable for mRNA decay, apoptosis induction, and cancer research. This guide connects practical ActD handling with an orthogonal strategy for studying RBMS1–B4GALT1–PD-L1 regulation in triple-negative breast cancer.
-
Tigecycline Assays for Carbapenem-Resistant CREC
2026-09-29
Tigecycline offers a useful glycylcycline antibiotic framework for studying carbapenem-resistant Enterobacter cloacae. This article connects plasmid transmission data from Guangdong hospitals with genotype-aware assay design, controls, and interpretation for multidrug-resistant bacteria research.
-
Dabigatran Safety: Lessons from a 2019 Review
2026-09-29
This review reframed Dabigatran safety around real-world adverse-event reports rather than anticoagulant efficacy alone. Its synthesis highlights bleeding, gastrointestinal and esophageal injury, allergic reactions, organ impairment, and acute coronary events, while proposing risk assessment and management considerations for clinical practice.
-
RNA Pol II Loss Activates Apoptosis Beyond Transcription
2026-09-28
Harper et al. show that RNA polymerase II inhibition kills cells through an active apoptotic signaling program rather than through passive depletion of mRNA and protein. Their identification of the Pol II degradation-dependent apoptotic response (PDAR) separates loss of RNA Pol IIA from loss of transcription and provides a framework for interpreting how diverse anticancer drugs can trigger mitochondrial cell death.
-
Thiamet G and Placental Ferroptosis Assay Logic
2026-09-28
Explore how Thiamet G, an O-GlcNAcase inhibitor, can help interrogate O-GlcNAc signaling in trophoblast ferroptosis. A new preeclampsia study connects HUWE1 modification to TfR1 turnover, iron uptake, and syncytialization—and offers practical guidance for designing causal assays.
-
Cy5 TSA Fluorescence System Kit in Plaque Biology
2026-09-27
The Cy5 TSA Fluorescence System Kit offers a spatially focused way to investigate inflammatory signals in atherosclerotic tissue. This article connects tyramide chemistry to a recent NLRP3 study while clarifying what amplified staining can—and cannot—show about disease mechanisms.
-
Mapping Metastatic Cell Identity with Cy5 TSA
2026-09-26
Metastatic head and neck cancer research increasingly depends on resolving where cellular identity changes occur—not only which genes change. This article connects recent HNSCC single-cell findings to spatial validation strategies, explaining how HRP-driven Cy5 tyramide deposition can help researchers investigate scarce targets while preserving tissue context.